

17224 U.S. PTO  
06/12/03




FIG. 1




FIG. 2

BEST AVAILABLE COPY

17224 U.S. PTO  
06/12/03




FIG. 3

BEST AVAILABLE COPY

17224 U.S. PTO  
06/12/03




FIG. 4

BEST AVAILABLE COPY




FIG. 5

17224 U.S. PTO  
06/12/03




FIG. 6

BEST AVAILABLE COPY




FIG. 7



1 GACTAGTGTATAAGTGCTGATGAGTCACAAGATAGATAACTATATTTTIGTCTATATTATA 60  
-35  
61 AAGTGTTTATAGTTAATTAATAATTAGTTAATTTCAAAAGTTGTATAAATAGGATAACTT 120  
-18 -35  
121 AATAAATGTAAGATAATAATTTGGAGGATAATTAACATGAAAAATAAATTGATAGCAAAA 180  
-18 M K N K L I A K  
181 TCTTTATTAACAATAGCGGCAATTGGTATTACTACAACACTACAATTGCGTCAACAGCAGAT 240  
S L L T I A A I G I T T T I A S T A D  
241 GCGAGCGAAGGATACGGTCCAAGAGAAAAGAAACCAGTGAGTATTAATCACAATATCGTA 300  
A↑S E G Y G P R E K K P V S I N H N I V  
301 GAGTACAATGATGGTACTTTTTAAATATCAATCTAGACCAAATTTAACTCAACACCTAAA 360  
E Y N D G T F K Y Q S R P K F N S T P K  
361 TATATTAAATTCAAACATGACTATAATATTTTAGAATTTAACGATGGTACATTCGAATAT 420  
Y I K F K H D Y N I L E F N D G T F E Y  
421 GGTGCACGTCCACAATTTAATAAACCAGCAGCGAAAACCTGATGCAACTATTAATAAAAGAA 480  
G A R P Q F N K P A A K T D A T I K K E  
481 CAAAAATTGATTCAAGCTCAAATCTTGTGAGAGAATTTGAAAAACACATACTGTCACT 540  
Q K L I Q A Q N L V R E F E K T H T V S  
541 GCACACAGAAAAGCACAAAAGGCAGTCAACTTAGTTTTGTTTGAATACAAAGTGAAGAAA 600  
A H R K A Q K A V N L V S F E Y K V K K  
601 ATGGTCTTACAAGAGCGAATTGATAATGTATTAACAAGGATTAGTGAGATAATACTTC 660  
M V L Q E R I D N V L K Q G L V R \*  
661 TGTCATTATTTTAAGTTCAAATAATTTAATATTATATTATTTTATTAATAAACGAC 720  
721 TATGCTATTTAATGCCAGGTTAATGTAACTTTCTAAAATTGACTATATAATCGTTAAGT 780  
781 ATCAATTTTAAGGAGAGTTTACAATGAAATTTAAAAATATATATTAACAGGAACATTAG 840  
M K F K K Y I L T G T L A  
841 CATTACTTTTATCATCAACTGGGATAGCAACTATAGAAGGGAATAAAGCAGATGCAAGTA 900  
L L L S S T G I A T I E G N K A D A S S  
901 GTCTGGACAAATATTTAACTGAAAGTCAGTTTCATGATAAACGCATAGCAGAAGAATTAA 960  
L D K Y L T E S Q F H D K R I A E E L R  
961 GAACTTTACTTAACAAATCGAATGTATATGCATTAGCTGCAGGAAGCTT 1009  
T L L N K S N V Y A L A A G S 1

FIG. 8



1 ATAGATACTATATTTTGTCTATATTATAAAGTGTTTATAGTTAATTAATAATTAGTTAA 60  
1 G CA 60

61 TTTCAAAAGTTGTATAAATAGGATAACTTAATAAATGTAAGATAATAATTTGGAGGATAA 120  
61 120

121 TTAACATGAAAAATAAATTGATAGCAAAATCTTTATTAACAATAGCGGCAATTGGTATTA 180  
121 G GC T A 180

181 CTACAACTACAATTGCGTCAACAGCAGATGCGAGCGAAGGATACGGTCCAAGAGAAAAGA 240  
181 240

241 AACCAGTGAGTATTAATCACAATATCGTAGAGTACAATGATGGTACTTTTAAATATCAAT 300  
241 300

301 CTAGACCAAATTTAACTCAACACCTAAATATATTAAATTCAAACATGACTATAATATTT 360  
301 360

361 TAGAATTTAACGATGGTACATTCGAATATGGTGCACGTCCACAATTTAATAAACCAGCAG 420  
361 420

421 CGAAAACTGATGCAACTATTAAAAAAGAACAAAAATTGATTCAAGCTCAAATCTTGTGA 480  
421 480

481 GAGAATTTGAAAAACACATACTGTCAGTGCACACAGAAAAGCACAAAAGGCAGTCAACT 540  
481 540

541 TAGTTTCGTTTGAATACAAAGTGAAGAAAATGGTCTTACAAGAGCGAATTGATAATGTAT 600  
541 600

601 TAAACAAGGATTAGTGAGATAATACTTCTGTCATTATTTTAAGTTCAAAA...TAATT 660  
601 T A A AA C GC G T TC GG TAAT 660

661 TAATATTATATTATTTTTTATTAATAAAACGACTATGCTATTTAATGCCAGGTTAATGTA 720  
661 A G G A G G AA G AT A 720

721 ACTTTCCTAAAATTGACTATATAATCGTTAAGTATCAATTTTAAGGAGAGTTTACAATGA 780  
721 T G G C AG C T 780

781 AATT 785  
781 785

FIG. 9





APPLN. FILING DATE: AUG. 27, 2001  
TITLE: FIBRINOGEN BINDING PROTEIN  
INVENTOR(S): WASTFELT ET AL  
APPLICATION SERIAL No: 09/938,497

SHEET 9 of 14

1 MKNKLIAKSLLTIAAIGITTTTIASTADASEGYGPREKKPVSINHNIVEYNDGTFKYQSR 60  
1 A L 60  
61 PKFNSTPKYIKFKHDYNILEFNDGTFEYGARPQFNKPAAKTDATIKKEQKLIQAQNLVRE 120  
61 120  
121 FEKTHTVSAHRKAQKAVNLVSFEYKVKMVLQERIDNVLKQGLVR 165  
121 K 165

FIG. 10



Fbg-bp, strain Newman:

SEGYGPR

EKKPVSINH	NIVEYNDGSFK	YQSRPKFNSTP
KYIKFKHDY	NILEFNDGTFE	YGARPPQFNKPA

AKTDA~~T~~IKKEQKLIQAQNLVREFEKTHTVSAHRKAQKAVNLVSFEYKVKKMLQERIDNVLKQGLVR

Coagulase, strain 8325-4:

(C-terminal fragment)

KYVKYRDAGT	ASQ	YGPRPQFNKTP
ETNAY	GIREYNDGTFG	YEARRPFNKPS
ETNAY	NVTTHANGQVS	YGARPTYKKPS
KTNAY	NVTTHANGQVS	YGARPTQNKPS
KTNAY	NVTTHGNGQVS	YGARQAQNKPS
KTNAY	NVTTHANGQVS	YGARPTYKKPS
KTNAY	NVTTHADGTAT	YGPRVTK

FIG. 11



FIG. 12

**Adherence and Internalisation to fibroblasts by  
Newman and Newman AH12 ( Eap::Ery<sup>R</sup> ) O.N culture**






FIG. 13

**Adherence and Internalization into epithelial cells of Newman  
and Newman AH12 (Eap::Ery<sup>R</sup>), O.N culture**






FIG. 14

**Adherence and Internalisation to epithelial cells by a 2 hours  
culture of Newman and Newman AH12 (Eap::Ery<sup>R</sup>)**






FIG. 15

**Internalisation to fibroblasts by strain Newman in the presence or absence of Eap-AB**

